Open Access to Large Scale Datasets Is Needed to Translate Knowledge of Cancer Heterogeneity into Better Patient Outcomes
article has not abstract
Vyšlo v časopise:
Open Access to Large Scale Datasets Is Needed to Translate Knowledge of Cancer Heterogeneity into Better Patient Outcomes. PLoS Med 12(2): e32767. doi:10.1371/journal.pmed.1001794
Kategorie:
Editorial
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001794
Souhrn
article has not abstract
Zdroje
1. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. (2010) International network of cancer genome projects. Nature 464: 993–998. doi: 10.1038/nature08987 20393554
2. Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153: 17–37. doi: 10.1016/j.cell.2013.03.002 23540688
3. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685–696. doi: 10.1038/nrg2841 20847746
4. Ding L, Wendl MC, McMichael JF, Raphael BJ (2014) Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 15: 556–570. doi: 10.1038/nrg3767 25001846
5. Garraway LA, Jänne PA (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2: 214–226. doi: 10.1158/2159-8290.CD-12-0012 22585993
6. Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338–345. doi: 10.1038/nature12625 24048066
7. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–892. doi: 10.1056/NEJMoa1113205 22397650
8. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, et al. (2013) Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231: 21–34. doi: 10.1002/path.4230 23780408
9. De Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, et al. (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (80-) 346: 251–256.
10. Burrell RA, Swanton C (2014) Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 8: 1095–1111. doi: 10.1016/j.molonc.2014.06.005 25087573
11. Schwarz RF, Trinh A, Sipos B, Brenton JD, Goldman N, et al. (2014) Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput Biol 10: e1003535. doi: 10.1371/journal.pcbi.1003535 24743184
12. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, et al. (2015) Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Reconstruction. PLoS Med 12: e1001789. doi: 10.1371/journal.pmed.1001789
13. Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106.
14. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, et al. (2014) Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst 106.
15. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW (2015) Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from the Cancer Genome Atlas. PLoS Med 12: e1001786. doi: 10.1371/journal.pmed.1001786
16. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157–1160. doi: 10.1126/science.1208130 21798893
17. Mroz EA, Rocco JW (2013) MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49: 211–215. doi: 10.1016/j.oraloncology.2012.09.007 23079694
18. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, et al. (2014) Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 20: 682–688. doi: 10.1038/nm.3559 24836576
19. Sage Bionetworks (2015) ICGC-TCGA DREAM Somatic Mutation Calling Challenge—Tumor Heterogeneity & Evolution. https://www.synapse.org/#!Synapse:syn2813581. Accessed 15 January 2015.
20. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90–94. doi: 10.1038/nature09807 21399628
21. Navin NE (2014) Cancer genomics: one cell at a time. Genome Biol 15: 452. doi: 10.1186/s13059-014-0452-9 25222669
22. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344: 1396–1401. doi: 10.1126/science.1254257 24925914
23. Lee JH, Daugharthy ER, Scheiman J, Kalhor R, Yang JL, et al. (2014) Highly multiplexed subcellular RNA sequencing in situ. Science 343: 1360–1363. doi: 10.1126/science.1250212 24578530
24. Ke R, Mignardi M, Pacureanu A, Svedlund J, Botling J, et al. (2013) In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods 10: 857–860. doi: 10.1038/nmeth.2563 23852452
25. Rimm DL (2014) Next-gen immunohistochemistry. Nat Methods 11: 381–383. doi: 10.1038/nmeth.2896 24681723
26. Angelo M, Bendall SC, Finck R, Hale MB, Hitzman C, et al. (2014) Multiplexed ion beam imaging of human breast tumors. Nat Med 20: 436–442. doi: 10.1038/nm.3488 24584119
27. Giesen C, Wang HAO, Schapiro D, Zivanovic N, Jacobs A, et al. (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 11: 417–422. doi: 10.1038/nmeth.2869 24584193
28. Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, et al. (2013) Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 110: 11982–11987. doi: 10.1073/pnas.1300136110 23818604
29. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101: 1446–1452. doi: 10.1093/jnci/djp335 19815849
30. Ahern TP, Hankinson SE (2011) Re: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 103: 1558–1559; author reply 1559–1560. doi: 10.1093/jnci/djr327 21917608
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2015 Číslo 2
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
- The Movement of Multidrug-Resistant Tuberculosis across Borders in East Africa Needs a Regional and Global Solution
- Enabling Dynamic Partnerships through Joint Degrees between Low- and High-Income Countries for Capacity Development in Global Health Research: Experience from the Karolinska Institutet/Makerere University Partnership
- The Role of Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans